Evidence reviews – August 2024
The following documents contain the evidence that was used to develop the 2024 recommendations:
- Prognostic factors for progression of non-proliferative diabetic retinopathy
- Different thresholds or criteria for starting treatment for non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, and diabetic macular oedema
- Effectiveness of intensive treatments to lower blood glucose levels
- Effectiveness of lipid modification therapies and antihypertensive medicines
- Effectiveness and acceptability of anti-vascular endothelial growth factor agents and laser photocoagulation (alone or in combination) for the treatment of non-proliferative and proliferative diabetic retinopathy
- Vitrectomy
- Effectiveness and acceptability of intravitreal steroids, macular laser and anti-vascular endothelial growth factor agents for treating diabetic macular oedema
- Clinical features for switching or stopping treatment for proliferative diabetic retinopathy or diabetic macular oedema
- Treatments before, during or after cataract surgery
- Effectiveness of different monitoring frequencies
- Diagnostic accuracy of ultrawide-field fundus photography and optical coherence tomography
Other supporting evidence
This page was last updated: